Australia markets closed

Neumora Therapeutics, Inc. (NMRA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.500.00 (0.00%)
At close: 04:00PM EDT
9.49 -0.01 (-0.11%)
After hours: 05:47PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-254,021
-235,925
-130,904
-237,312
-99,272
Depreciation & amortisation
668
668
594
538
105
Stock-based compensation
22,418
17,240
8,298
4,274
1,675
Change in working capital
-5,617
-8,899
-6,948
-961
-3,124
Accounts payable
6,586
-581
-1,246
-759
-4,673
Other working capital
-173,273
-163,395
-115,407
-76,237
-28,060
Other non-cash items
67,356
67,379
15,349
158,094
70,772
Net cash provided by operating activities
-173,192
-163,278
-114,896
-75,420
-26,760
Cash flows from investing activities
Investments in property, plant and equipment
-
-117
-511
-817
-1,300
Purchases of investments
-253,393
-109,072
-226,369
0
-
Sales/maturities of investments
170,408
178,166
71,867
0
-
Other investing activities
-
-4,590
-13,000
-
-9,937
Net cash used for investing activities
-88,431
64,387
-168,013
-817
-11,237
Cash flows from financing activities
Common stock issued
-
233,375
0
960
3,190
Common stock repurchased
-
-491
0
0
-2
Other financing activities
-
-3,804
-744
-1,141
-
Net cash used provided by (used for) financing activities
233,680
231,936
115,743
293,507
230,099
Net change in cash
-27,943
133,045
-167,166
217,270
192,102
Cash at beginning of period
212,083
242,206
409,372
192,102
0
Cash at end of period
184,140
375,251
242,206
409,372
192,102
Free cash flow
Operating cash flow
-173,192
-163,278
-114,896
-75,420
-26,760
Capital expenditure
-
-117
-511
-817
-1,300
Free cash flow
-173,273
-163,395
-115,407
-76,237
-28,060